Universität zu Köln

Berg, Linn Persson, Eriksson, Marcus, Longhi, Sonia, Kockum, Ingrid ORCID: 0000-0002-0867-4726, Warnke, Clemens ORCID: 0000-0002-3510-9255, Thomsson, Elisabeth, Backstrom, Malin, Olsson, Tomas, Fogdell-Hahn, Anna and Bergstrom, Tomas (2022). Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment. BMJ Neurol Open, 4 (2). LONDON: BMJ PUBLISHING GROUP. ISSN 2632-6140

Full text not available from this repository.

Abstract

Background Patients with multiple sclerosis (MS) demonstrate higher seroprevalence of Epstein-Barr virus (EBV) and increased anti-EBV IgG levels in serum compared with healthy controls. Intrathecal antibody production to measles virus (MeV) is a common finding in patients with MS. Objective To measure serum IgG reactivity to EBV glycoprotein 350 (gp350) and MeV nucleocapsid protein (N-CORE) in patients with MS and healthy controls and to determine if reactivity changed in patients during interferon beta (IFN beta) and/or natalizumab (NAT) treatment. A secondary aim was to determine the seroprevalence of EBV in patients and controls. Methods Patients with MS (n=728) were included from the Swedish pharmacovigilance study for NAT. Paired serum samples from 714 patients drawn before and during NAT treatment and paired samples from 170 patients during prior IFN beta treatment were analysed. In total, 156 patients were included in both groups. Samples from 144 matched blood donors served as controls. Indirect ELISA was applied using recombinant EBVgp350 and MeV N-CORE as antigens. EBVgp350 IgG seronegative samples were also analysed using EBV nuclear antigen 1 and viral capsid antigen (VCA). Results Patients with MS showed higher serum levels of anti-EBVgp350 and anti-MeV N-CORE IgG compared with controls. During NAT treatment, the levels of anti-EBVgp350 and anti-MeV N-CORE IgG declined, compared with the relatively stable levels noted during prior IFN beta treatment. Ten patients failed to demonstrate anti-EBVgp350 IgG but did show detectable anti-VCA IgG, indicating EBV seropositivity. In contrast, 10/144 controls were EBV seronegative. Conclusions Treatment with NAT, which is considered a selective immunosuppressive agent with a compartmentalised effect on the central nervous system, appeared to be associated with a moderate decrease in circulating IgG levels to EBVgp350 and MeV N-CORE. All patients with MS were EBV IgG seropositive, supporting the potential role of EBV in the pathogenesis of MS.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Berg, Linn Persson UNSPECIFIED UNSPECIFIED UNSPECIFIED Eriksson, Marcus UNSPECIFIED UNSPECIFIED UNSPECIFIED Longhi, Sonia UNSPECIFIED UNSPECIFIED UNSPECIFIED Kockum, Ingrid UNSPECIFIED orcid.org/0000-0002-0867-4726 UNSPECIFIED Warnke, Clemens UNSPECIFIED orcid.org/0000-0002-3510-9255 UNSPECIFIED Thomsson, Elisabeth UNSPECIFIED UNSPECIFIED UNSPECIFIED Backstrom, Malin UNSPECIFIED UNSPECIFIED UNSPECIFIED Olsson, Tomas UNSPECIFIED UNSPECIFIED UNSPECIFIED Fogdell-Hahn, Anna UNSPECIFIED UNSPECIFIED UNSPECIFIED Bergstrom, Tomas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-688081
DOI:	10.1136/bmjno-2022-000271
Journal or Publication Title:	BMJ Neurol Open
Volume:	4
Number:	2
Date:	2022
Publisher:	BMJ PUBLISHING GROUP
Place of Publication:	LONDON
ISSN:	2632-6140
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INFECTIOUS-MONONUCLEOSIS; ANTIBODY-LEVELS; RISK; ASSOCIATION; VACCINE; MARKER Multiple languages Clinical Neurology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68808